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Abstract  
INTRODUCTION: In patients with an implanted pacemaker, asymptomatic atrial fibrillation (AF) is 
associated with an increased risk of thrombo-embolic complications. There is still no consensus 
which duration of episodes of atrial fibrillation should be taken as an indicator for inclusion of oral 
anticoagulation therapy (OAC).  
MATERIAL AND METHODS: A total of 104 patients who had no AF episodes in the past and have 
an indication for permanent pacing were included in the study.  
RESULTS: During an average follow-up of 18 months, 33 of the patients developed episodes of 
AF. Inclusion of OAC was performed in 17 patients, in whom AF was recorded, although in all 
patients CHA2DS2-VASc score was ≥ 1. The inclusion of OAC showed a statistically significant 
correlation with increasing duration of episodes of AF (r = 0.502, p = 0.003). During the follow-up 
period none of the patients developed thrombo-embolic complication.  
CONCLUSION: Considering that our group of patients had no thrombo-embolic events, we could 
conclude that dividing the AF episodes in less than 1% in 24 hours and longer than 1% within 24 
hours could be an indicator for decision-making to include OAK if the CHA2DS2-VASc score is ≥ 1. 
 
 
 
 
 
Introduction 
 
Atrial fibrillation (AF) is the most common 
arrhythmia, whose incidence increases with age, and 
the prevalence in the general population is 1.5-2% [1]. 
AF is associated with twofold increase in mortality, 
threefold increase in the incidence of congestive heart 
failure and fivefold increase in the incidence of stroke 
[1, 2]. 
Oral anticoagulation (OAC) therapy 
significantly decreases the risk of stroke in all AF-
patients [3, 4], but it increases the risk of bleeding. 
CHA2DS2 VASc score has been shown to be the best 
marker for detecting patients with very low risk for 
thrombo-embolic complications who do not benefit 
from OAC therapy [1].  
Although AF is usually associated with 
palpitations, dyspnea, chest pain, anxiety, at least one 
third of patients with AF are completely asymptomatic. 
But the risk of stroke is equal whether AF is 
symptomatic or asymptomatic [5, 6].  
One of the biggest challenges in this field is to 
identify patients with asymptomatic paroxysmal AF, 
and if indicated, that is, if CHA2DS2-VASc score is 1 or 
more than 1, to introduce OAC therapy. 
AF can be very efficiently detected in patients 
with implanted pacemaker and the detection of atrial 
high rate episodes (AHRE) - defined as episodes of 
atrial frequency ≥220 bpm, lasting ≥5 minutes, has 
been proven to be an independent predictor of death 
or nonfatal stroke in these patients [7].
 
 
Previous studies have shown that in 90% of 
patients with implanted dual-chamber pacemakers, 
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episodes of AF are asymptomatic, because of the lack 
of irregular ventricular contraction during arrhythmia 
[7, 8]. 
There is still no firm evidence on the duration 
of the AF-episode as a risk of thrombo-embolic 
complications and whether this risk increases with 
frequency, duration of a single episode or AF burden 
within a certain period of time. The optimal 
antithrombotic management in patients without atrial 
fibrillation, but with atrial high rate episodes, is not 
known.  
The aim of this study was to evaluate the 
anticoagulation management in patients with atrial 
fibrillation detected from implanted pacemakers.  
 
 
Patients and Methods 
 
A total of 104 patients with an indication for 
dual chamber pacemaker implantation were selected 
from the Clinic of Cardiology in the period from 
January 2013 to December 2014. Inclusion criteria in 
the study were no previous documented episodes of 
AF. 
According to the indication and the decision of 
the cardiologist DDD, DDDR or VDD pacemaker was 
implanted on the non-dominant hand-side using 
standard procedure. The pacemaker was 
programmed in DDD, DDDR or VDD mode of 
stimulation with lower rate limit set at 60 bpm. No 
antiarrhythmic interventional algorithm was used. 
Atrial sensing was programmed at 30% of the 
measured P wave to avoid atrial over-sensing, or 
under-sensing. To prevent tracking fast atrial rhythms, 
mode switch was programmed at 175 bpm. Every 
pacemaker was programmed to record and show the 
maximum number of recorded episodes of high 
frequency atrial episodes.  
Sensitivity and specificity for detection of atrial 
high rate episodes from the implanted devices was 
established in previous studies and it exceeds 95% 
[9]. 
Follow-up of patients was at one-month after 
implantation and every six months afterwards up to 24 
months. At follow-up visits, patients were examined, 
pacemakers interrogated and therapies adjusted.  
At each pacemaker interrogation the 
occurrence of atrial high rate episodes was monitored, 
their frequency and duration and mode-switch 
episodes. Patients with paroxysmal AF episodes were 
divided in two groups: patients who had episodes of 
AF <1% in 24h and patients who had episodes of AF 
>1% in 24h.  
In patients who experienced persistent AF 
during the follow-up period, an attempt was made to 
restore sinus rhythm following anticoagulation 
according to the Guidelines for the management of 
atrial fibrillation [1, 2]. If this attempt was 
unsuccessful, permanent AF was accepted.  
During the follow-up period every initiation of 
the OAC therapy was recorded, and it was made by 
the decision by an attending cardiologist. OAC 
therapy was either Vitamin K antagonist 
(acenocumarol) or non-vitamin K antagonist (NOAC).  
 
Statistical analysis 
Categorical parameters were summarized as 
percentages and continuous parameters as mean ± 
SD. Comparisons between the two groups was 
performed using the Student’s t-test for continuous 
parameters and the Pearson’s chi-square test for 
categorical parameters. Assessment of correlation 
was done using the Spearman’s correlation analysis. 
Multiple logistic regression analysis was performed in 
stepwise order to determine independent predictors of 
OAC use.  
All data analysis was performed using 
commercially available statistical programs and a p 
value ≤ 0.05 was considered significant. 
 
 
Results 
 
Patients included in this study had a mean 
age of 66.3  8.7 years, predominantly of male gender 
(62.5%).  
Regarding pharmacological therapy, patients 
were treated mainly with angiotensin converting 
enzyme inhibitor (79 patients / 76.0 %), beta 
adrenergic blockers (26 patients / 25%), diuretics (46 
patients / 54.2 %), acetyl- salicylic acid (48 patients / 
46.2 %) and antiarrhythmics (8 patients / 7.2 %), of 
which 4 patients were treated with amiodarone and 
other 4 with calcium channel blockers. In 14 patients 
(13.5 %) during the follow up period beta blockers 
were added by the decision of the attending 
cardiologist. 
During the average follow-up period of 18
 
months, from a total of 104 patients, 33 (31.7%) 
developed episodes of atrial fibrillation. Episodes with 
duration of <1% in 24 hours were observed in 20 
(60.6%) patients, episodes > 1% in 24 hours were 
observed in 6 (18.2%) patients, persistent AF was 
diagnosed in 3 (9.1%) patients, and permanent AF 
was diagnosed in 4 (12.1%) patients. Spontaneous 
conversion to sinus rhythm occurred in 25 (75.8%) 
patients, drug conversion to sinus rhythm (with 
amiodarone) was conducted in 3 (9.1%) patients, and 
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electrical cardio-version was performed in one (3.0%) 
patient. 
In terms of symptoms, asymptomatic 
episodes of AF were observed in 22 (66.7%) patients 
and symptomatic episodes in 11 (33.3%) patients. 
The average time to detection of AF episodes was 
1.39 ± 3.3 months from the beginning of the follow-up. 
CHA2DS2-VASc risk score for susceptibility 
to the development of thrombo-embolic complications 
in all patients with AF was ≥1, which means oral 
anticoagulant therapy was indicated in all these 
patients, since the diagnosis of AF was made.  
Despite that, OAC therapy was given to 17 
patients only, out of 33 patients who experienced AF. 
OAC was given to 1 patient (3.0%) after 1 month 
follow-up, to 7 patients (21.2%) after 6 months follow-
up, to 6 patients (18.2%) after 12 months follow-up, to 
2 patients (6.0%) and to 1 patient (3.0%) after 24 
months follow-up. 
A comparison of the initiation of OAC in 
patients with symptomatic or asymptomatic AF during 
the follow-up period showed a statistically significant 
difference between these two groups of patients (p = 
0.006; Figure 1). Thus, a significantly larger 
percentage of patients with asymptomatic AF were not 
treated with OAC compared to patients with 
symptomatic AF (15 / 68.2% vs. 1 / 9.1%, 
respectively). 
 
Figure 1: Anticoagulation initiation in percentages during follow-up 
in months in patients with asymptomatic vs. symptomatic atrial 
fibrillation 
 
The inclusion of OAC therapy showed a 
statistically significant correlation with increasing 
length of duration of AF episodes (r = 0.502, p = 
0.003). Regarding the timing of their involvement and 
the duration of AF, a statistically significant difference 
(p = 0.003) was observed between the group of 
patients with duration of <1% in 24 hours compared to 
all the other patients (Figure 2). OAC usually was not 
given to patients with short duration of AF episodes. 
In order to see if there is a possible 
connection to the inclusion of OAC with certain 
demographic, clinical, and pacemaker features 
analysis of correlations was made and the results are 
presented in Table 1. Overall, these results indicate 
that the presence of CAD, diabetes, arterial 
hypertension (borderline significance), are significantly 
associated with the inclusion of OAC. Prolonged 
duration of AF and associated symptoms 
(symptomatic patients) are also significantly 
associated with the given OAC. Interestingly, 
administration of OAC was not statistically significantly 
associated with the value of CHA2DS2-VASc score. 
 
Figure 2: Anticoagulation initiation in percentages during follow-up 
in months in patients with atrial fibrillation episodes with different 
duration (<1%/24h, vs. all others) 
 
Variables presented in Table 1 were used for 
multivariate regression analysis in order to determine 
predictors for using OAC, and longer duration of AF 
(divided in <1% in 24 h and all others) has emerged 
as a significant independent predictor for inclusion of 
OAC (Table 2). It means that for every unit extension 
of the duration of the AF, decision to give OAC 
increases for 0.722 times (95 % CI 0.382-1.062, p = 
0.0001).  
Table1. Correlation of OAC initiation with tested parameters 
Parameters Correlation 
Coronary artery disease (%) r = 0.366; p = 0.033 
Diabetes mellitus (%) r = 0.344; p = 0.046 
Arterial hypertension (%) r = 0.311; p = 0.074 
Therapy with beta blockers (%) r = 0.609; p = 0.0001 
P wave duration on ECG (ms) r = -0.387; p = 0.024 
AF duration  (<1%/24h vs. all others) r = 0.658; p = 0.0001 
AF (paroxysmal, persistent, permanent) r = 0.661; p = 0.0001 
Symptomatic AF (%) r = 0.557; p = 0.001 
Cumulative ventricular pacing 
   Month 1 
   Month 6 
 
r = -0.398; p = 0.032 
r = -0.372; p = 0.056 
Cumulative dual chamber pacing 
   Month 1 
   Month 6 
 
r = -0.390; p = 0.037 
r = -0.349; p = 0.075 
Searched AV on (%) 
r = 0.625; p = 0.030 
AF -atrial fibrillation; ECG –electrocardiography; AV -atrio-ventricular. 
 
The assessment of the predictive value of the 
variables included in the model made with the Dubin-
Watson’s test showed a value of 1.85, which 
confirmed that the variable is a truly independent 
predictor and is responsible for 66.7% of all reasons 
for inclusion of OAC in the therapy. 
During the follow-up period none of the 
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patients developed any thrombo-embolic 
complication. 
Table 2: Multiple regression analysis for OAC initiation as a 
dependent variable from clinical features and duration of the 
AF as independent predictive variables 
Coefficients
a
 
Model 
Unstandardized 
Coefficients 
Standar-
dized 
Coeffi-
cients 
t p 
95% Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
1- Constant 
  - OAC <1, all others 
-0.444 
0.722 
0.229 
0.165 
0.667 
-1.994 
4.382 
0.064 
0.000 
-0.916 
0.382 
0.027 
1.062 
a) Dependent Variable: OAC yes, no  
 
 
 
Discussion  
 
According to the results of studies in patients 
with implanted devices AF daily burden is associated 
with an increased risk of ischemic stroke or transient 
ischemic attack [10, 11]. In our study during the 
follow-up period none of the patients has experienced 
ischemic stroke or transient ischemic attack, or any 
other thrombo-embolic complication. All patients who 
developed episodes of AF, according to CHA2DS2-
VASc score which was ≥1, had an indication for OAC, 
but OAC was given only to 17 patients (51%) out of 
33. 
Patients with persistent and permanent AF 
(21% of all patients with AF) were mainly 
symptomatic, and OAC was given to all of them 
except one (Figure 2). 
Patients with paroxysmal AF (79%) divided 
into two groups - patients with episodes of AF <1% in 
24 hours (20 patients, or 60.6%) and patients with 
episodes of AF > 1% in 24h (6 patients, or 18.2%), 
showed a statistically significant correlation of OAC 
with increasing length of duration of AF episodes (r = 
0.502, p = 0.003). OAC was not given to patients with 
short duration of AF episodes.  
In the ASSERT study atrial high rate 
episodes, defined as episodes with heart rate above 
190/min with a minimum duration of 6 minutes, 
increased the risk of thrombo-embolic complications 
(stroke or peripheral embolism) two times and also 
increased the risk of occurrence of clinically apparent 
AF [12]. Also, the higher risk of stroke was found in 
patients with higher CHADS VASc score. A question 
remains whether these short episodes of AF have 
direct connection with thrombus formation and further 
thrombo-embolic complications or simply indicate 
existence of changes in the atrial endothelium which 
are transient or persistent and increase the risk of 
stroke [13, 14]. 
Unlike the ASSERT study, the MOST study 
demonstrated a temporal relationship of AF episodes 
with stroke, but the duration of significant episodes of 
AF was defined as 5.5 h [7]. This was not confirmed in 
further studies. Although subclinical AF is associated 
with an increased risk of thrombo-embolic 
complications, very few patients had AF within the 
month before the acute thrombo-embolic event. This 
was presented in the Brambatti M et al. study, being 
an extension of the ASSERT study [15]. In other 
words, the temporal relationship between episodes of 
AF with subsequent thrombo-embolic complications 
needs to be clarified. 
Capucci et al. found that in patients with dual-
chamber pacemakers atrial high rate episodes longer 
than 5 minutes did not significantly increase thrombo-
embolic risk, whereas episodes lasting longer than 24 
h increased it (odds ratio 3.1) [16].  
Notably on the other side, the results of the 
IMPACT trail showed that early initiation of OAC 
based on device-detected subclinical AF did not 
improve outcomes, in part because of temporal 
dissociation between AF and stroke, and possibly 
because of stroke mechanisms independent of AF 
[17]. The results of the IMPACT trial do not support 
urgent initiation of OAC and recommend decision for 
initiation of OAC based on individualized assessment 
of risk and benefit [17]. 
Nevertheless, we know that many of the 
patients with detected atrial high rate episodes 
develop clinical AF over time, and these episodes 
could be considered as a precursor of paroxysmal AF. 
Having in mind that OAC can produce bleeding 
complications there is still uncertainty about the 
optimal antithrombotic therapy in patients with 
subclinical AF.  
In conclusion, the inclusion of OAC in patients 
with AF demonstrated a statistically significant 
correlation with the increasing duration of the 
episodes, with most OAC not given in patients with 
short duration of episodes (<1% in 24h). 
Given that in our patients thrombo-embolic 
complications were not recorded, maybe the decision 
of the doctors to give or not OAC based on duration of 
the AF episode, with cut-off value longer or shorter 
than 1% in 24h was right, provided CHA2DS2-VASc 
score is ≥1.  
Waiting for the results from the large trials 
addressing this issue - optimal antithrombotic therapy 
in patients with atrial high rate episodes: NOAH – 
AFNET 6 (Non-vitamin K antagonist oral 
anticoagulants in patients with atrial high rate 
episodes) and ARTESIA (Apixaban for the reduction 
of thrombo-embolism in patients with device-detected 
sub-clinical atrial fibrillation), we could follow the 
strategy to start with OAC if the detected atrial high 
rate episodes exceed >1% of the time in 24 h.  
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